[1] Sherman R E, Anderson S A, Dal Pan G J, et al. Real-World Evidence - What Is It and What Can It Tell Us?[J]. New England Journal of Medicine, 2016, 375(23):2293-2297. [2] FDA. Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices[EB/OL].[2016-07-27](2017-05-08). https://www.fda.gov/downloads/medicaldevices/ deviceregulationandguidance/guidancedocuments/ucm513027.pdf. [3] Jr G L, Neumann P J, Erickson P, et al. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report[J]. Value in Health the Journal of the International Society for Pharmacoeconomics & Outcomes Research, 2007, 10(5):326-335. [4] 黄卓山,罗艳婷.真实世界研究的方法与实践[J].循证医学,2015,14(6):365-268. [5] 徐菲,刘国恩.真实世界研究与药物经济学评价[J].中国药物经济学,2015,(10):8-10. [6] 张彦红,梁伟雄,朱磊,等.实用性临床试验与解释性临床试验的比较[J].中国中西医结合杂志,2009,29(2):161-164. [7] 陈薇,刘建平. 注册研究的定义、设计及国内外进展[J].现代中医临床, 2014, 21(6):23-25. [8] Bate A, Juniper J, Lawton A M, et al. Designing and incorporating a real world data approach to international drug development and use: what the UK offers[J]. Drug Discovery Today, 2015, 21(3):400-405. [9] 杨薇,谢雁鸣.美国AHRQ《评估患者结局的注册登记指南(第2 版)》解读[J].中国中药杂志,2013,38(18):2958-2962. [10] CMS. Coverage with Evidence Development[EB/OL].(2015- 04-10)[2017-05-08]. https://www.cms.gov/Medicare/Coverage/ Coverage-with-Evidence-Development/. [11] FDA.FDA's Sentinel Initiative - Background[EB/OL].(2016-10-05)[2017-05-08]. https://www.fda.gov/Safety/ FDAsSentinelInitiative/ucm149340.htm. [12] 边蕾,赵频,杨悦.FDA前哨行动运行情况研究与启示[J].中 国药物警戒 ,2013,10(1):25-29. [13] USA CONGRESS. H.R.34 - 21st Century Cures Act[EB/OL].(2016-12-13)[2017-05-08]. https://www.congress.gov/bill/ 114th-congress/house-bill/34/text?q=%7B%22search%22%3A%5B%2221st+Century+Cures+Act%22%5D%7D&r=3. [14] FDA.PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2018 Through 2022[EB/OL].(2017-03-28)[2017-05-08].https://www.fda.gov/downloads/ForIndustry/ UserFees/PrescriptionDrugUserFee/UCM511438.pdf. [15] USA.ClinicalTrials.gov[EB/OL].(2017-04-12)[2017-05-08]. https://clinicaltrials.gov/ct2/results?term=REAL+WORLD+STUDY &Search=Search. [16] The Academy of Medical Sciences. Real world evidence[EB/OL].(2015-09-17)[2017-05-08]. https://acmedsci.ac.uk/more/events/ real-world-evidence-workshop. [17] EMA. Highlights from the “Workshop on methods for efficacy studies in the everyday practice”[EB/OL].(2013-12-09)[2017-05-08].http://www.ema.europa.u/docs/en_GB/ document_library/Minutes/2013/11/WC500155692.pdf. [18] EMA. Scientific guidance on post-authorisation efficacy studies [EB/OL].(2016-10-12)[2017-05-08].http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/12/ WC500219040.pdf. [19] EMA.Adaptive pathways[EB/OL].(2015-06-01)[2017-05-08]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/ general/general_cotent_000601jsp&mid=WC0b01ac05807d58ce. [20] EMA.Workshop on identifying opportunities for ‘big data’ in medicines development and regulatory science[EB/OL].(2016-11-14)[2017-05-08].http://www.ema.europa.eu/ema/ index.jsp curl=pages/news_and_events/events/2016/08/event_ detail_001314.jsp&mid=WC0b01ac058004d5c3. [21] 王玲.试论医疗大数据给药品安全性监测与评价带来的机遇和挑战[J].中国药物警戒,2015,12(11):660-664. [22] Olariu E, Papageorgakopoulou C, Bovens S M, et al. Real World Evidence in Europe: A Snapshot of its Current Status[J]. Value In Health, 2016, 19(7):A347-A766. [23] IMI GetReal.[EB/OL].[2017-05-01][2017-05-08].https://www.imi-getreal.eu/. [24]国务院印发.《促进大数据发展行动纲要》[EB/OL].[2015-09-05](2017-05-08).http://www.gov.cn/zhengce/content/ 2015-09/05/content_10137.htm. [25] 国家食品药品监督管理局安监司.关于征求《关于推动生产企业开展药品重点监测工作的通知(征求意见稿)》意见的函[EB/OL].(2013-03-25)[2017-05-08]. http://www.sda.gov.cn/WS01/CL0778/79321.html. |